| Literature DB >> 28291796 |
Angelina Huseinovic1, Jolanda S van Leeuwen2, Tibor van Welsem3, Iris Stulemeijer3, Fred van Leeuwen3, Nico P E Vermeulen1, Jan M Kooter4, J Chris Vos1.
Abstract
Acetaminophen (APAP), although considered a safe drug, is one of the major causes of acute liver failure by overdose, and therapeutic chronic use can cause serious health problems. Although the reactive APAP metabolite N-acetyl-p-benzoquinoneimine (NAPQI) is clearly linked to liver toxicity, toxicity of APAP is also found without drug metabolism of APAP to NAPQI. To get more insight into mechanisms of APAP toxicity, a genome-wide screen in Saccharomyces cerevisiae for APAP-resistant deletion strains was performed. In this screen we identified genes related to the DNA damage response. Next, we investigated the link between genotype and APAP-induced toxicity or resistance by performing a more detailed screen with a library containing mutants of 1522 genes related to nuclear processes, like DNA repair and chromatin remodelling. We identified 233 strains that had an altered growth rate relative to wild type, of which 107 showed increased resistance to APAP and 126 showed increased sensitivity. Gene Ontology analysis identified ubiquitin homeostasis, regulation of transcription of RNA polymerase II genes, and the mitochondria-to-nucleus signalling pathway to be associated with APAP resistance, while histone exchange and modification, and vesicular transport were connected to APAP sensitivity. Indeed, we observed a link between ubiquitin levels and APAP resistance, whereby ubiquitin deficiency conferred resistance to APAP toxicity while ubiquitin overexpression resulted in sensitivity. The toxicity profile of various chemicals, APAP, and its positional isomer AMAP on a series of deletion strains with ubiquitin deficiency showed a unique resistance pattern for APAP. Furthermore, exposure to APAP increased the level of free ubiquitin and influenced the ubiquitination of proteins. Together, these results uncover a role for ubiquitin homeostasis in APAP-induced toxicity.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28291796 PMCID: PMC5349473 DOI: 10.1371/journal.pone.0173573
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Deletion of DDR genes MMS2, UBC13, and RFX1 confers resistance to APAP.
Fivefold serial dilutions of a cell suspension of the mutant strains with optical density OD600 = 0.05 were plated on YPD plates containing 0, 50 and 75 mM APAP and incubated for one (control) and three days at 37°C. After three days, the 75 mM plate was transferred to room temperature (RT) for 6 days. The strains used were WT (BY4741), Δmms2, Δubc13, Δrad5 and Δrfx1.
APAP resistant and sensitive strains and GO enrichment of biological processes, presented in alphabetical order.
| 107 out of 1522 | ||
| GO term | Genes | p-value |
| Protein ubiquitination (18 out of 101) | 8,09E-05 | |
| Transcription initiation from RNA polymerase II promoter (8 out of 33) | 1,20E-03 | |
| Mitochondria-nucleus signaling pathway (4 out of 5) | 9,98E-05 | |
| 72 out of 1522 | ||
| GO term | Genes | p-value |
| Protein-DNA complex subunit organization (17 out of 86) | 9.11E-04* | |
| Chromatin remodeling (12 out of 58) | 6.60E-03* | |
| 53 out of 1522 | ||
| GO term | Genes | p-value |
| Protein transport and establishment of protein localization (24 out of 205) | 6.52E-05* | |
| Vesicle-mediated transport (17 out of 47) | 6.47E-03* | |
| Cytoplasm-to-vacuole targeting (CVT) pathway (8 out of 18) | 2.08E-04* | |
Note: p values marked with * are calculated with Holm-Bonferroni correction. Only the values of p<0.05 are listed in the table. DAmP strains are marked in bold.
Genes related to protein (de)ubiquitination processes that mediate APAP tolerance as described in the Saccharomyces Genome Database.
| Gene | Function |
|---|---|
| Subunit of the Anaphase-Promoting Complex/Cyclosome (APC/C), a ubiquitin-protein (E3) ligase required for degradation of anaphase inhibitors. | |
| 14-3-3 protein; controls proteome at post-transcriptional level, involved in regulation of exocytosis, vesicle transport, Ras/MAPK signaling, and rapamycin-sensitive signaling. | |
| Subunit of the Anaphase-Promoting Complex/Cyclosome (APC/C), a ubiquitin-protein (E3) ligase required for degradation of anaphase inhibitors. | |
| Ubiquitin-conjugating enzyme (E2) and catalytic subunit of SCF ubiquitin-protein (E3) ligase complex that regulates cell cycle progression by targeting key substrates for degradation. | |
| Component of the CCR4-NOT complex, which has multiple roles in regulating mRNA levels. It contributes to ubiquitin-protein transferase activity. | |
| Ubiquitin-protein (E3) ligase, required for ubiquitin-dependent degradation of the RNA Polymerase II subunit Rpo21. | |
| WD repeat protein required for ubiquitin-mediated protein degradation, ubiquitin binding cofactor that complexes with Cdc48p, required for ribophagy, controls cellular ubiquitin concentration. | |
| Peptidylprolyl-cis/trans-isomerase; regulates phosphorylation of the RNA polymerase II large subunit (Rpo21p) C-terminal domain. | |
| Ubiquitin-protein (E3) ligase required for endoplasmic reticulum-associated degradation (ERAD) of misfolded proteins. | |
| Ubiquitin-conjugating (E2) enzyme variant involved in error-free post-replication repair; forms a heteromeric complex with Ubc13. | |
| Essential conserved subunit of CPF cleavage and polyadenylation factor;; contains a ubiquitin-like (UBL) domain, possible role in ubiquitination of Pap1p. | |
| E3 ubiquitin ligase targeting centromere-binding protein Cse4p. | |
| Ubiquitin-protein (E3) ligase involved in ubiquitin-mediated protein degradation; functions in multivesicular body sorting, heat shock response and ubiquitylation of arrested RNAPII. | |
| Ubiquitin-conjugating (E2) enzyme. | |
| Ubiquitin-conjugating (E2) enzyme involved in error-free DNA post-replication repair; interacts with Mms2. | |
| Ubiquitin, encoded as a polyubiquitin precursor. | |
| F-box protein and component of SCF ubiquitin E3 ligase complexes. | |
| ATP-dependent RNA helicase of the SFI superfamily involved in nonsense mediated mRNA decay. Reported E3 ligase via its association with Upf3. | |
| Component of the nonsense-mediated mRNA decay (NMD) pathway, along with (E3) Upf1. |
Note: DAmP strains are presented in bold.
Fig 2APAP resistance of ubiquitin deficient strains.
Five-fold dilution of WT (BY4741), Δubi4, Δdoa1, Δubp6 and Δdoa4 cells were spotted on YPD plates with or without 70 mM APAP and grown at 37°C for three and four days, respectively.
Fig 3Ubiquitin overexpression confers APAP sensitivity.
Strains WT, Δmms2, Δubc13, Δubi4, Δubp6 and Δdoa1 were transformed with a multicopy plasmid expressing a ubiquitin gene from the UBI4 promoter and an empty plasmid as a control. A spotting assay was performed on YPD plates containing 70, 80 and 90 mM APAP (A). A spotting assay performed with WT cells on YPD plates containing 50 and 60 mM APAP (B). YPD plates without APAP were the control. The plates were incubated at 37°C for 3 days for APAP containing plates and 2 days for the control plate. All strains exhibited higher sensitivity to APAP upon ubiquitin overexpression.
Fig 4APAP affects levels of free ubiquitin in yeast.
The WT, Δubi4, Δdoa1 and Δubp6 cells were grown exponentially and treated with 0, 25 or 50 mM APAP for 2 hrs at 37°C before harvesting. 4A) Western blot with antibodies against ubiquitin. 4B) Western blot with anti-actin antibodies was used as an internal control for loading.
Fig 5Ubiquitin deficient strains are uniquely APAP resistant and sensitive for a variety of chemicals.
The individual dots represent five-fold dilution of the cells: they were spotted on YPD plates with and without the chemicals. The overall conditions were: 70 mM APAP, 90 mM AMAP, 4 mM quinine and 400 μg/μl rapamycin all grown for 5 days; 1 μg/ml cadmium, 0.1 mM arsenic (III)-oxide, 50 mM H2O2, 0.25 μM cycloheximide (CHX), 30μg/ml benomyl, 0.01% MMS and 15 μM FTY20, all grown for three days; and 2.5 mM ibuprofen grown for 6 days. The plates were incubated at 37°C.
Fig 6Model to illustrate the effect of APAP on various cellular processes through ubiquitination.
In WT cells, the APAP-induced changes in ubiquitination lead to a growth arrest, while in ubiquitin-depleted mutants growth arrest is prevented and cells become resistant.